WANBURY · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 42/100 — Quality 43 · Valuation 33 · Momentum 55
| Share price | ₹339.90 |
| Market cap | ₹1,041 Cr |
| P/E ratio | 15.3 |
| P/B ratio | 16.5 |
| ROCE | 28.4% |
| Book value | ₹18.09 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹650 Cr | ₹66 Cr | 14.2% |
| 2025 | ₹600 Cr | ₹31 Cr | 13.0% |
| 2024 | ₹557 Cr | ₹56 Cr | 13.0% |
| 2023 | ₹485 Cr | ₹-10 Cr | 5.0% |
| 2022 | ₹511 Cr | ₹81 Cr | 7.0% |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines, antitussives, analgesics, antidepressants, and anti-inflammatory medicines. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited wa